Best 3 ASX Penny Stocks to Watch in 2026

These three ASX-listed companies are showing positive growth with Atomic Eagle advancing its uranium projects, Prescient Therapeutics progressing its clinical program, and EDU Holdings growing student enrolments.

Atomic Eagle Limited (ASX: AEU)

Atomic Eagle Limited (ASX: AEU), on 24 June 2026, announced that the Muntanga Uranium Project in Zambia received Environmental and Social Impact Assessment approval from the Zambia Environmental Management Agency and “No Objection” approval for the Resettlement Action Plan from the Office of the Vice President. These approvals are the key environmental and social requirements before future construction and reduce permitting risks.

The company stated that Muntanga remains focused on resource growth and optimisation. The strategy includes expanding the mineral resource through the ongoing 30,000m drilling program, adding resources not included in the previous feasibility study, and improving the project scale and configuration. Development timing will depend on future technical work, project outcomes, and market conditions.

On 17 June 2026, Atomic Eagle provided an update on the Madaouela Uranium Project, confirming discussions with Niger’s Ministry of Mines regarding a possible new mining convention. The negotiations remain incomplete and non-binding.

Prescient Therapeutics Limited (ASX: PTX)

Prescient Therapeutics Limited (ASX: PTX) reported on 30 April 2026 its March 2026 Quarterly Activities Report reflecting ongoing success in the PTX-100 clinical program. The Phase 2a recruitment grew due to international expansion with 11 active sites in March 2026 and 12 sites at the end of the quarter. Total patient enrolment reached 18, with the study planned for up to 40 patients. The company ended the quarter with cash and term deposits of $11.93 million after receiving a $4.3 million R&D tax refund.

During the quarter, the company continued its collaboration with CSIRO to study PTX-100’s activity. Artificial intelligence and computational modelling created a three-dimensional model showing PTX-100’s interaction with its target protein and its selective binding ability.

Prescient also continued assessing future PTX-100 opportunities in Peripheral T Cell Lymphoma. PTX-100 remains focused on CTCL, where existing treatment options have limited effectiveness and durability. 

EDU Holdings Limited (ASX: EDU)

EDU Holdings Limited (ASX: EDU), on 15 June 2026, reported T2’26 enrolment growth with total student enrolments rising 32% to 7,036 compared with the previous corresponding period. New student enrolments increased 12% to 963, with Higher Education contributing 91% of commencements. The Group continued its focus on higher education through Ikon Institute and vocational education through Australian Learning Group.
Higher Education enrolments reached 5,847, up 57% from the previous period. Growth came from international demand, domestic student increases and postgraduate programs. Domestic new student enrolments rose 98%, while postgraduate new student enrolments increased 174%. The company also continued implementing its onshore recruitment model following National Code amendments.

EDU Holdings Limited maintained its FY26 outlook, expecting revenue, EBITDA and NPAT growth related with FY25. EDU continues investing in recruitment channels and course expansion even though balancing growth funding, financial strength and shareholder returns through dividends and share buybacks.

(Source: Company Report)